A Phase II Study of SAR650984 in Patients with Multiple Myeloma

Full Title

A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies

Purpose

In this study, researchers are evaluating the safety and effectiveness of the investigational drug SAR650984 in patients with multiple myeloma that has come back after previous treatment. SAR650984 is an antibody designed to stop myeloma growth by binding to a protein on myeloma cells called CD38. SAR650984 is given intravenously (by vein).

While this is a Phase I/II study, Memorial Sloan Kettering is participating only in the Phase II portion.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that has come back after at least three prior regimens of therapy OR myeloma that continued to grow while being treated with a combination of a proteasome inhibitor (such as bortezomib or carfilzomib) and an immunomodulatory drug (such as lenalidomide, thalidomide, or pomalidomide).
  • Patients must have recovered from the serious side effects of previous treatments.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Nikoletta Lendvai at 212-639-3368.

Protocol

14-216

Phase

I/II

Investigator

Co-Investigators

Locations